U.S. Bodily Remedy (USPH) got here out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.62 per share a yr in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of 1.47%. 1 / 4 in the past, it was anticipated that this doctor staffing providers firm would publish earnings of $0.81 per share when it truly produced earnings of $0.73, delivering a shock of -9.88%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates two instances.
U.S. Bodily Remedy
The sustainability of the inventory’s instant value motion primarily based on the recently-released numbers and future earnings expectations will principally depend upon administration’s commentary on the earnings name.
U.S. Bodily Remedy shares have misplaced about 11.1% for the reason that starting of the yr versus the S&P 500’s acquire of 19.8%.
What’s Subsequent for U.S. Bodily Remedy?
Whereas U.S. Bodily Remedy has underperformed the market up to now this yr, the query that involves buyers’ minds is: what’s subsequent for the inventory?
There are not any simple solutions to this key query, however one dependable measure that may assist buyers deal with that is the corporate’s earnings outlook. Not solely does this embody present consensus earnings expectations for the approaching quarter(s), but in addition how these expectations have modified recently.
Empirical analysis reveals a robust correlation between near-term inventory actions and traits in earnings estimate revisions. Traders can monitor such revisions by themselves or depend on a tried-and-tested ranking device just like the Zacks Rank, which has a powerful monitor file of harnessing the ability of earnings estimate revisions.
Forward of this earnings release, the estimate revisions development for U.S. Bodily Remedy: blended. Whereas the magnitude and path of estimate revisions may change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out in step with the market within the close to future. You may see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will probably be fascinating to see how estimates for the approaching quarters and present fiscal yr change within the days forward. The present consensus EPS estimate is $0.71 on $172.98 million in revenues for the approaching quarter and $2.58 on $659.78 million in revenues for the present fiscal yr.
Traders ought to be aware of the truth that the outlook for the trade can have a fabric influence on the efficiency of the inventory as effectively. When it comes to the Zacks Trade Rank, Medical – Outpatient and Dwelling Healthcare is at the moment within the prime 17% of the 250 plus Zacks industries. Our analysis reveals that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
Astrana Well being, Inc. (ASTH), one other inventory in the identical trade, has but to report outcomes for the quarter ended September 2024. The outcomes are anticipated to be launched on November 7.
This firm is anticipated to publish quarterly earnings of $0.33 per share in its upcoming report, which represents a year-over-year change of -29.8%. The consensus EPS estimate for the quarter has been revised 4% decrease over the past 30 days to the present degree.
Astrana Well being, Inc.’s revenues are anticipated to be $462.01 million, up 32.7% from the year-ago quarter.
Analysis Chief Names “Single Greatest Decide to Double”
From 1000’s of shares, 5 Zacks specialists every have chosen their favourite to skyrocket +100% or extra in months to return. From these 5, Director of Analysis Sheraz Mian hand-picks one to have probably the most explosive upside of all.
This firm targets millennial and Gen Z audiences, producing practically $1 billion in income final quarter alone. A current pullback makes now an excellent time to leap aboard. In fact, all our elite picks aren’t winners however this one may far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
U.S. Physical Therapy, Inc. (USPH) : Free Stock Analysis Report
Astrana Health, Inc. (ASTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
